Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,115 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Colorectal Cancer Clear all
Completed Phase 2 Interventional Results available

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

NCT00578721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

NCT01596634
View directory record Official record
Conditions
Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy
Interventions
questionnaire administration, quality-of-life assessment, laboratory biomarker analysis, bovine lactoferrin
Other · Procedure · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 4, 2026, 5:14 PM EDT
Recruiting Phase 2 Interventional

Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

NCT06824064
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions
RBS2418, Placebo
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Newark, Delaware • Kingwood, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706
View directory record Official record
Conditions
Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions
MRTX1133
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening

NCT01634126
View directory record Official record
Conditions
Colorectal Cancer
Interventions
1 FIT kit, 2 FIT kit
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 75 Years
Enrollment
2,761 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Sep 4, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

NCT07321106
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
Interventions
CBI-1214
Biological
Lead sponsor
Cartography Biosciences
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308
View directory record Official record
Conditions
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up

NCT00697047
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Automated Mailing, Automated Mailing Plus Assisted, Auto Plus Assisted Plus Navigation
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years to 73 Years
Enrollment
4,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 4, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

NCT07416552
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
3
States / cities
Omaha, Nebraska • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 4, 2026, 5:14 PM EDT
Recruiting Phase 1 Interventional

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT07337525
View directory record Official record
Conditions
Advanced Malignant Solid Tumor, Solid Tumor Cancer
Interventions
PLT012
Drug
Lead sponsor
Pilatus Biosciences Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

NCT00501410
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-FU, Cetuximab, Dasatinib, Leucovorin, Oxaliplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Colorectal Cancer Awareness, Research, Education and Screening (CARES)

NCT01804179
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Immunochemical Fecal Occult Blood Test (I-FOBT) Kit, Standard Intervention (SI) Educational Materials, CARES Intervention Educational Materials, Baseline Visit Survey, Follow-up Questionnaire
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 4, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002842
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 4, 2026, 5:14 PM EDT
Not listed No phase listed Observational

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
Not listed
Lead sponsor
Andrew Kennedy
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 4, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional Results available

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions
V941, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 4, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening for Familial Colorectal Cancer (CRC) Patients

NCT00632515
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 60 Years
Enrollment
269 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening

NCT04607291
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Community Health Service, Survey Administration
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 4, 2026, 5:14 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Placebo, Metformin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma

NCT00773097
View directory record Official record
Conditions
Risk for Colorectal Cancer
Interventions
MUC1 - Poly ICLC
Biological
Lead sponsor
Robert Schoen
Other
Eligibility
40 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT of Automated Telephone Outreach to Improve Colorectal Cancer Screening

NCT00792285
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Automated Telephone Outreach with Speech Recognition
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
50 Years to 64 Years
Enrollment
80,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2008 · Synced Sep 4, 2026, 5:14 PM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 4, 2026, 5:14 PM EDT